STOCK TITAN

Form 144 shows Hims & Hers insider to offload 125k shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Hims & Hers Health (HIMS) has filed a Form 144 disclosing CEO Andrew Dudum’s intention to sell up to 125,335 Class A shares (≈ $6.21 million) through Fidelity Brokerage on or after 21 Jul 2025. The proposed block equals 0.06 % of the 215.5 million shares outstanding.

The notice also lists prior insider activity: entities tied to Dudum disposed of ≈ 463,000 shares between 28 Apr and 16 Jul 2025, generating roughly $26.9 million in gross proceeds. Individual sales ranged from 2,792 to 128,127 shares.

No operational or financial metrics accompany the filing; Form 144 only signals planned insider sales. Although the volume is small relative to float, continued CEO selling can pressure sentiment. Investors may watch for additional filings, confirmation of a 10b5-1 plan, or further ownership changes.

Positive

  • None.

Negative

  • CEO Andrew Dudum plans to sell 125,335 shares worth ≈ $6.21 M, adding to ≈ 463 k shares sold over the prior three months.
  • Continued insider selling may signal weaker confidence or create negative sentiment despite representing only 0.27 % of outstanding shares year-to-date.

Insights

TL;DR: Modest-sized CEO sale; sentiment risk, but not quantitatively material.

The proposed 125 k-share sale is just 0.06 % of outstanding stock and follows several similar disposals totalling ~463 k shares in three months. While insider selling often triggers caution, the percentages are minor and no adverse business information is alleged. Absence of earnings data or guidance leaves the sale’s motive unclear. Impact on valuation should be limited unless selling accelerates or aligns with negative fundamentals.

TL;DR: Repeated CEO disposals warrant monitoring for governance optics.

Founders selling into market rallies can be routine liquidity events, yet multiple sales in quick succession may raise perception issues around long-term commitment. Transparency via Form 144 limits regulatory risk, but investors may press for clarity on any 10b5-1 plan and remaining insider ownership levels. Without that context, governance sentiment could tilt negative even if economic impact is small.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many HIMS shares is the CEO planning to sell?

The Form 144 covers up to 125,335 Class A shares.

What is the approximate market value of the planned sale?

At recent prices the block is worth about $6.21 million.

When can the shares be sold?

The approximate sale date listed is 21 July 2025.

How many shares has Andrew Dudum sold in the last 3 months?

Entities linked to him sold ≈ 463,000 shares between 28 Apr and 16 Jul 2025.

What percentage of total shares does the new Form 144 represent?

Only 0.06 % of the 215.5 million shares outstanding.

Which broker will handle the transaction?

Fidelity Brokerage Services LLC is listed as the executing broker.